15 Posts From ASCO24 Day 5 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31st to June 4th 2024.
Our team at OncoDaily selected the most important posts from Day 5 of ASCO24 that you should not miss.
Incredible American Society of Clinical Oncology 2024 (ASCO24) is over but ASCO’s great mission in Conquering Cancer is ongoing.
From one great Robin Zon theme to another:
- The Art and Science of Oncology, from comfort to cure.
- Driving knowledge to action.
Building a Better Future.
What an inspiring time at the ASCO24 annual meeting with our team at Moffitt and over 40,000 peers.
- More than 80 team members in attendance
- Science that will change practice
- Countless connections with colleagues
- So much hope for cancer patients everywhere
Coming together at the ASCO annual meeting is essential. Collaboration and the science shared these last few days will impact the many lives touched by cancer.
Proud of our team and all the bright minds who contribute to this collective mission!
As the sun sets on ASCO24 I’d be remiss not to say that I’m worried about my colleagues. I worry we are crushing one another with colossal expectations, with our emails and CVs. You are more than your publications and presentations.
Please don’t tie your self-worth to brass rings. And, on a personal note, it took me a LONG time to separate my patient outcomes from my self-esteem as an oncologist. Here’s to being the inward beneficiaries of the same compassion we show our patients
Until next year …Please be kind to yourself,
Mark.
As ASCO24 concludes, I’ll fondly remember the great panel discussion with Drs. Suresh S. Ramalingam, Leticia Varella, Nazli Dizman, Fawzi F Abu Rous about becoming an oncologist in the US as an immigrant, just hours before Dr. Ramalingam’s Plenary Session of the significant LAURA trial results.
Thank you to ASCO members, leadership and staff for the most wonderful opportunity of a lifetime! This is my first official picture wearing the President badge!
ASCO staff you rock!
ASCO24 has been such a wonderful experience. The research presentations, patient stories, and array of professionals are truly inspiring. With each step, I am reminded of the wide gaps in cancer control between the global north and south.
I look forward to a time we can provide the infrastructure, organization, resources and content to host such gatherings at the same scale in Africa.
Leaving my first American Society of Clinical Oncology 2024 (ASCO24) not only with science shared and learned in Genito-Urinary Syndrome of Menopause (GUSM) and beyond but also warm moments spent with newly met colleagues and friends at various stages of their careers, each with unique dreams and aspirations.
Hope to see you soon! Missing Tanya Jindal.
One of the most important presentations of ASCO24: expansion cohorts from TBCRC 048, presented by Nadine Tung.
Among patients with MBC, olaparib achieved:
- ORR 76% in gPALB2 mut carriers
- ORR 37% in sBRCA mutation carriers
- Terrific effort fromThe TBCRC (make sure to follow for more!)
And that’s a wrap on ASCO24! This meeting fuels my soul and brain every year. Thank you ASCO for reminding us of our purpose.
Dr Bobby Daly at ASCO24 on impressive benefits of a virtual health integrative medicine intervention during routine cancer treatment.
This randomized trial decreased unplanned hospitalizations and hospitalization days and shows early survival benefit -not quite statistically significant (yet).
I think the most impactful CNS oncology data at ASCO24 … nicely done, Mehdi Touat and colleagues. Years from now, CODEL may simply affirm this result.
Always equal parts discovery and excitement, ASCO’s yearly meeting never disappoints. From major scientific advances and trial results earning standing ovations to insightful panels and case sessions, the overall takeaway to me was clear: there has never been a better day in human history to have OR fight cancer.
All-time best survivals, jaw-dropping Kaplan-Meier curves, and continuous advances in our understanding of the emperor of all maladies.
As an AI optimist, I was thrilled to see the lightbulbs going on for many colleagues during the AI sessions. I was proud to be a Faculty presenter alongside Drs. Judy Gichoya, Martina Murphy, and Shaalan Beg at our session entitled “Harness Artificial Intelligence to Enhance Patient–Physician Relationships.”
The energy and enthusiasm at ASCO are unmatched, and it’s inspiring to be part of such a forward-thinking community. What were your key takeaways from ASCO this year? Let’s keep the conversation going!
GIANT trial in more than 70 years/vulnerable Pancreatic ductal adenocarcinoma (PDAC) American Society of Clinical Oncology 2024 (ASCO24) as by geriatric assess.
- Important to remember most on PDAC trials less than 70 years.
- Dose modified Gemcitabine plus nab-Paclitaxel (GnP) versus 5‐Fluorouracil (5FU) liposomal irinotecan.
- Sobering med Overall Survival (OS) by Intention-To-Treat (ITT) 4.7 versus 4.4 months.
- Need to identify who can benefit and discuss with patients.
What a week! ASCO24 and CancerX Moonshot hosted by Atrium Health all across 7 days of learning, networking, connecting with friends and colleagues and being home again in my beautiful city of Chicago!
I feel blessed to be doing this work with SurvivorPlan and to have the opportunity to collaborate and connect with so many bright and passionate people.
As ASCO24 comes to an end.. my key reflections are:
- Science keeps delivering life-saving and breakthrough results in the long lasting battle against cancer.
- Cancer is not any more the classical definition we used to describe in last few years, we keep dissecting patients with biomarkers and identify tailored treatment strategies.
- The more we know, the more questions come up and the less we know… so we will keep digging for answers.
Full respect to scientists, patients, caregivers and everyone who has contributed to what we know..
We carry the responsibility of sharing what we learned to patients, policy makers and society to transform science into real life practice.
